|
US5494660A
(en)
*
|
1985-06-18 |
1996-02-27 |
Emory University |
Method for inhibiting microbial binding to surfaces
|
|
US5466445A
(en)
*
|
1985-06-18 |
1995-11-14 |
Emory University |
Methods for reducing salmonella in chickens
|
|
USRE35862E
(en)
*
|
1986-08-18 |
1998-07-28 |
Emisphere Technologies, Inc. |
Delivery systems for pharmacological agents encapsulated with proteinoids
|
|
US5541155A
(en)
*
|
1994-04-22 |
1996-07-30 |
Emisphere Technologies, Inc. |
Acids and acid salts and their use in delivery systems
|
|
US5451410A
(en)
*
|
1993-04-22 |
1995-09-19 |
Emisphere Technologies, Inc. |
Modified amino acids for encapsulating active agents
|
|
US5447728A
(en)
*
|
1992-06-15 |
1995-09-05 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
|
AU741590B2
(en)
*
|
1994-05-24 |
2001-12-06 |
Yeda Research And Development Co. Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
IL113812A
(en)
*
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
AU775214B2
(en)
*
|
1994-05-24 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
RU2198900C2
(en)
*
|
1994-05-24 |
2003-02-20 |
Еда Рисерч энд Дивелопмент Ко., Лтд. |
Improved copolymer-1 and method of preparation thereof
|
|
US6090958A
(en)
*
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
US5820881A
(en)
*
|
1995-04-28 |
1998-10-13 |
Emisphere Technologies, Inc. |
Microspheres of diamide-dicarboxylic acids
|
|
US5824345A
(en)
*
|
1995-06-07 |
1998-10-20 |
Emisphere Technologies, Inc. |
Fragrances and flavorants
|
|
IL116559A
(en)
|
1995-11-17 |
2005-11-20 |
Yissum Res Dev Co |
Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
|
|
US6214791B1
(en)
*
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
US5804688A
(en)
*
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5962710A
(en)
*
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
|
EP1105414A2
(en)
|
1998-07-23 |
2001-06-13 |
President And Fellows of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
ES2527760T3
(en)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Treatment of Crohn's disease with copolymer 1 and polypeptides
|
|
CA2337688C
(en)
|
1998-07-23 |
2016-04-05 |
Yeda Research And Development Co., Ltd. |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US7083777B1
(en)
*
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
|
US6531130B1
(en)
*
|
1999-07-06 |
2003-03-11 |
The Board Of Trustees Of The Leland Stanford University |
Treatment of demyelinating autoimmune disease with ordered peptides
|
|
WO2005046719A1
(en)
|
2003-11-12 |
2005-05-26 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
ES2243450T3
(en)
*
|
2000-01-20 |
2005-12-01 |
Yeda Research And Development Co. Ltd. |
THE USE OF COPOLIMERO 1 AND PEPTIDES AND RELATED POLYPEPTIDES, AND OF T-CELLS TREATED WITH THE SAME, FOR NEUROPROTECTOR THERAPY.
|
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
MXPA02007109A
(en)
*
|
2000-06-07 |
2002-12-13 |
Yeda Res & Dev |
THE USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND T-CELLS TREATED WITH THESE TO PROTECT THE CENTRAL NERVOUS SYSTEM CELLS FROM THE TOXICITY OF GLUTAMATE.
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
AU6887101A
(en)
*
|
2000-06-20 |
2002-01-02 |
Caprion Pharmaceuticals, Inc. |
Copolymers and methods of treating prion-related diseases
|
|
IL137460A0
(en)
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
|
SV2003000753A
(en)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
|
|
JP4369234B2
(en)
*
|
2001-12-04 |
2009-11-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
Method for measuring the strength of glatiramer acetate
|
|
CN102151330B
(en)
*
|
2001-12-06 |
2017-04-12 |
耶达研究及发展有限公司 |
Vaccine and method for treatment of motor neurone diseases
|
|
WO2004043995A2
(en)
*
|
2002-11-13 |
2004-05-27 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
AU2004227852B2
(en)
*
|
2003-03-31 |
2010-01-14 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
|
EP1680087A1
(en)
*
|
2003-10-31 |
2006-07-19 |
Teva Pharmaceutical Industries Limited |
Nanoparticles for drug delivery
|
|
WO2005085323A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Peptimmune, Inc. |
Methods and compositions for treatment of autoimmune diseases
|
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
|
WO2005120542A2
(en)
|
2004-05-07 |
2005-12-22 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
WO2005112911A2
(en)
*
|
2004-05-21 |
2005-12-01 |
The Regents Of The University Of California |
Compositions and methods for treating myelin deficiency disorders
|
|
US20060229233A1
(en)
|
2004-06-25 |
2006-10-12 |
Id Biomedical Corporation |
Compositions and methods for treating neurological disorders
|
|
DK1797109T3
(en)
*
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
US7495072B2
(en)
*
|
2004-09-09 |
2009-02-24 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
CA2583589C
(en)
*
|
2004-10-29 |
2012-04-24 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
ZA200705874B
(en)
*
|
2005-02-02 |
2009-04-29 |
Teva Pharma |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
WO2007022193A2
(en)
*
|
2005-08-15 |
2007-02-22 |
Wai Hong Chan |
Process for the preparation of copolymer-1
|
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
|
EP2013628B1
(en)
|
2006-04-28 |
2016-01-06 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating peptide mixtures
|
|
KR100831796B1
(en)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
Image display device with time shift function and its reproduction method
|
|
EP2046366B1
(en)
|
2006-06-28 |
2016-08-31 |
Yeda Research And Development Company Limited |
Copolymer-1 for treatment of age-related macular degeneration
|
|
WO2008121836A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Brigham And Women's Hospital, Inc. |
Compounds and methods for enhancing mhc class ii therapies
|
|
EP2381254B2
(en)
*
|
2007-06-21 |
2017-07-19 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
EP2173766A1
(en)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
US20090035816A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Scinopharm Taiwan Ltd. |
Process for the preparation of a polypeptide
|
|
WO2009040814A1
(en)
|
2007-09-24 |
2009-04-02 |
Hadasit Medical Research Services & Development Ltd |
Use of copolymer 1 for treatment of muscular dystrophy
|
|
EP2277050B2
(en)
*
|
2008-04-16 |
2022-09-28 |
Momenta Pharmaceuticals, Inc. |
Analysis of amino acid copolymer compositions
|
|
AU2009279636A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
|
AR074881A1
(en)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
A PROCESS TO PURIFY A MIXTURE OF POLYMERS
|
|
RU2402576C1
(en)
*
|
2009-02-20 |
2010-10-27 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Peptide copolymer, synthesis method thereof and pharmaceutical composition based on said copolymer
|
|
RU2011144566A
(en)
|
2009-04-03 |
2013-05-10 |
Момента Фармасьютикалз, Инк. |
CONTROL OF COPOLYMER COMPOSITIONS
|
|
AU2009347384B2
(en)
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
|
EP2405749B1
(en)
|
2009-08-20 |
2013-05-08 |
Yeda Research and Development Co., Ltd. |
Low frequency glatiramer acetate therapy
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
HRP20182076T1
(en)
|
2010-01-04 |
2019-02-08 |
Mapi Pharma Limited |
CONTROLLED RELEASE SYSTEM COVERING GLATIRAMER ACETAT
|
|
US20130035390A1
(en)
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
|
BR112013008573A2
(en)
|
2010-10-11 |
2016-07-12 |
Teva Pharma |
biomarker cytokines as indicators of clinical response to glatiramer acetate.
|
|
WO2012054518A1
(en)
*
|
2010-10-18 |
2012-04-26 |
Lanco Biosciences, Inc. |
Delivery of copolymers by microinjection systems
|
|
CA2827275A1
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
EP2699317B1
(en)
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
|
EP2731617A4
(en)
|
2011-07-12 |
2015-07-01 |
Brigham & Womens Hospital |
LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
|
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
CN103957705A
(en)
|
2011-10-10 |
2014-07-30 |
泰华制药工业有限公司 |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
|
MX2015004563A
(en)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarkers predictive for clinical response for glatiramer acetate.
|
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
|
DK2774639T3
(en)
|
2013-03-08 |
2015-01-12 |
Teva Pharma |
Reusable injection device for a syringe
|
|
RS53779B1
(en)
|
2013-03-08 |
2015-06-30 |
Teva Pharmaceutical Industries Ltd. |
Injectable Reusable Injection Device
|
|
EP2971173A4
(en)
|
2013-03-14 |
2016-11-23 |
Mylan Inc |
GLATIRAMERATE ACETATE POWER TEST BY MRM RESPONSE BIOMARKERS
|
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
CN103265624B
(en)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
Method for preparing copaxone
|
|
UY35790A
(en)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
|
|
CA2928084A1
(en)
|
2013-10-24 |
2015-04-30 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
|
JP2017503169A
(en)
|
2013-12-31 |
2017-01-26 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
Diagnosis of systemic lupus erythematosus using oligonucleotide antigens
|
|
BR112016020919A2
(en)
|
2014-03-12 |
2018-01-23 |
Yeda Res & Dev |
reduced levels or systemic activity of regulatory t cells for the treatment of snc disease and injury
|
|
DK3185882T3
(en)
|
2014-08-29 |
2020-01-27 |
Region Midtjylland |
Positively charged copolymers for use as antimicrobial agents
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US11047855B2
(en)
|
2015-03-01 |
2021-06-29 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
|
CN108135167B
(en)
|
2015-08-19 |
2021-07-09 |
哈佛学院院长及董事 |
Lipidated PSA compositions and methods
|
|
ES2744179T3
(en)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Analysis of the molecular weight distribution of complex polypeptide mixtures
|
|
EP3170836B1
(en)
|
2015-11-23 |
2018-10-24 |
Chemi SPA |
Rp-hplc analysis of complex polypeptide mixtures
|
|
WO2018002930A1
(en)
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
EP3484441A4
(en)
|
2016-07-15 |
2020-03-18 |
President and Fellows of Harvard College |
GLYCOLIPID COMPOSITIONS AND METHODS OF USE
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
FI3506921T3
(en)
|
2016-08-31 |
2023-07-21 |
Mapi Pharma Ltd |
Depot systems comprising glatiramer acetate
|
|
MX2019010174A
(en)
|
2017-03-26 |
2019-10-15 |
Mapi Pharma Ltd |
Glatiramer depot systems for treating progressive forms of multiple sclerosis.
|
|
CA3062964C
(en)
|
2017-05-15 |
2024-11-12 |
Mapi Pharma Ltd. |
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
|
|
AU2018270396B2
(en)
|
2017-05-15 |
2025-03-20 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|